Table 1 : Overview of the formulations used for the in vivo tests. All NLC formulations contained a 10 % lipid phase (lipid+drug) dispersed in a Tween 80 solution of 1 % or 2 %


Formulation Composition

Andriol in Tween 80 solution 25 mg TU solution from Andriol Testocaps capsule dispersed in 500 µl Tween 80 solution 0.1 %
Andriol in Castor Oil/Lauroglycol solution from Andriol Testocaps capsule diluted to 1 % TU content with castor oil and Lauroglycol FCC
TU Nanosuspension 1 % TU in 0.2 % sodium dodecylsulfat solution
T Nanosuspension 1 % T in 0.2 % sodium dodecylsulfat solution
NLC 30 %  Dynasan (approx. 200 nm) 30 % TU in Dynasan  118/oleic acid (50/50) in 2 % Tween 80 solution
NLC 30 % Dynasan (approx. 600 nm) 30 % TU in Dynasan 118/oleic acid (50/50) in 1 % Tween 80 solution
NLC 15 %  Dynasan (approx. 200 nm) 15 % TU in Dynasan 118/oleic acid (50/50) in 2 % Tween 80 solution
NLC 15 %  stearic acid (approx. 200 nm) 15 % TU in hr acid/oleic acid (50/50) in 2 % Tween 80 solution

M Keck et al.Journal of Pharmaceutical Technology and Drug Research  2013 2:4DOI : 10.7243/2050-120X-2-4